CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival

Pancreas

Volumn 43, Issue 3, 2014, Pages 380-388

  Lee, Sang Hyub ^a,b   Kim, Haeryoung ^a,c   Hwang, Jin Hyeok ^a   Shin, Eun ^a,c   Lee, Hye Seung ^a,c   Hwang, Dae Wook ^a,c   Cho, Jai Young ^a,c   Yoon, Yoo Seok ^a,c   Han, Ho Seong ^a,c   Cha, Byung Hyo ^d  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Cheju Halla General Hospital   (South Korea)

Author keywords

CD24; Epithelial to mesenchymal transition; Immunohistochemistry; Pancreatic cancer; Prognosis; S100A4

Indexed keywords

CALVASCULIN; CD24 ANTIGEN; EZRIN; GELATINASE A; HERMES ANTIGEN; NERVE CELL ADHESION MOLECULE; TRANSCRIPTION FACTOR SNAIL; TUMOR MARKER; UROKINASE RECEPTOR; UVOMORULIN; VIMENTIN; CYTOSKELETON PROTEIN; PROTEIN S 100; S100A4 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS ADENOCARCINOMA; PERINEURAL INVASION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR INVASION; ADENOCARCINOMA; BIOSYNTHESIS; CARCINOMA, PANCREATIC DUCTAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; OUTCOME ASSESSMENT; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; ANTIGENS, CD24; ANTIGENS, CD44; CARCINOMA, PANCREATIC DUCTAL; CYTOSKELETAL PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; S100 PROTEINS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84896616347     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000097     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
2. Zuckerman DS, Ryan DP. Adjuvant therapy for pancreatic cancer: A review. Cancer. 2008;112:243-249.
3. Stathis A, Moore MJ. Advanced pancreatic carcinoma: Current treatment and future challenges. Nat Rev Clin Oncol. 2010;7:163-172.
4. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80:1529-1537.
5. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-1428.
6. Olmeda D, Jorda M, Peinado H, et al. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene. 2007;26:1862-1874.
7. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?. Nat Rev Cancer. 2007;7:415-428.
8. Santisteban M, Reiman JM, Asiedu MK, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69:2887-2895.
9. Elloul S, Elstrand MB, Nesland JM, et al. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005;103:1631-1643.
10. Shioiri M, Shida T, Koda K, et al. Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer. 2006;94:1816-1822.
11. Kwok WK, Ling MT, Lee TW, et al. Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res. 2005;65:5153-5162.
12. Wu Y, Deng J, Rychahou PG, et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell. 2009;15:416-428.
13. Miyazaki N, Abe Y, Oida Y, et al. Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100-4 expression. Int J Oncol. 2006;28:1369-1374.
14. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871-890.
15. Ai KX, Lu LY, Huang XY, et al. Prognostic significance of S100-4 and vascular endothelial growth factor expression in pancreatic cancer. World J Gastroenterol. 2008;14:1931-1935.
16. Hotz B, Arndt M, Dullat S, et al. Epithelial to mesenchymal transition: Expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res. 2007;13:4769-4776.
17. Cates JM, Byrd RH, Fohn LE, et al. Epithelial-mesenchymal transition markers in pancreatic ductal adenocarcinoma. Pancreas. 2009;38:e1Ye6.
18. Oida Y, Yamazaki H, Tobita K, et al. Increased S100-4 expression combined with decreased E-cadherin expression predicts a poor outcome of patients with pancreatic cancer. Oncol Rep. 2006;16:457-463.
19. Cui Y, Li T, Zhang D, et al. Expression of Ezrin and phosphorylated Ezrin (pEzrin) in pancreatic ductal adenocarcinoma. Cancer Invest. 2010;28:242-247.
20. Hong SM, Li A, Olino K, et al. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol. 2011;24:1237-1247.
21. Hildenbrand R, Niedergethmann M, Marx A, et al. Amplification of the urokinase-Type plasminogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically high-risk group. Am J Pathol. 2009;174:2246-2253.
22. Mani SA, GuoW, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
23. Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010;102:340-351.
24. Javle MM, Gibbs JF, Iwata KK, et al. Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer. Ann Surg Oncol. 2007;14:3527-3533.
25. Arumugam T, Ramachandran V, Fournier KF, et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009;69:5820-5828.
26. Mahon PC, Baril P, Bhakta V, et al. S100-4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer. Cancer Res. 2007;67:6786-6795.
27. Ambartsumian N, Klingelhofer J, Grigorian M, et al. The metastasis-Associated Mts1(S100-4) protein could act as an angiogenic factor. Oncogene. 2001;20:4685-4695.
28. Gongoll S, Peters G, Mengel M, et al. Prognostic significance of calcium-binding protein S100-4 in colorectal cancer. Gastroenterology. 2002;123:1478-1484.
29. Nakamura T, Ajiki T, Murao S, et al. Prognostic significance of S100-4 expression in gallbladder cancer. Int J Oncol. 2002;20:937-941.
30. Rudland PS, Platt-Higgins A, Renshaw C, et al. Prognostic significance of the metastasis-inducing protein S100-4 (p9Ka) in human breast cancer. Cancer Res. 2000;60:1595-1603.
31. Yonemura Y, Endou Y, Kimura K, et al. Inverse expression of S100-4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res. 2000;6:4234-4242.
32. Rosty C, Ueki T, Argani P, et al. Overexpression of S100-4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am J Pathol. 2002;160:45-50.
33. Tabata T, Tsukamoto N, Fooladi AA, et al. RNA interference targeting against S100-4 suppresses cell growth and motility and induces apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009;390:475-480.
34. Kristiansen G, Machado E, Bretz N, et al. Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab Invest. 2010;90:1102-1116.
35. Kristiansen G, Schluns K, Yongwei Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer. 2003;88:231-236.
36. Su MC, Hsu C, Kao HL, et al. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett. 2006;235:34-39.
37. Yang XR, Xu Y, Yu B, et al. CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. Clin Cancer Res. 2009;15:5518-5527.
38. Sano A, Kato H, Sakurai S, et al. CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol. 2009;16:506-514.
39. Ikenaga N, Ohuchida K, Mizumoto K, et al. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas. Hum Pathol. 2010;41:1466-1474.
40. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030-1037.
41. Zhang Y, Wei J, Wang H, et al. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep. 2012;27:1599-1605.